摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(5-Methyl-thien-2-yl) 3,4-dihydro-4,4-dimethyl-7-bromo-naphthalene | 204449-11-6

中文名称
——
中文别名
——
英文名称
1-(5-Methyl-thien-2-yl) 3,4-dihydro-4,4-dimethyl-7-bromo-naphthalene
英文别名
1-(5-Methyl-thien-2-yl)3,4-dihydro-4,4-dimethyl-7-bromo-naphthalene;2-(7-bromo-4,4-dimethyl-3H-naphthalen-1-yl)-5-methylthiophene
1-(5-Methyl-thien-2-yl) 3,4-dihydro-4,4-dimethyl-7-bromo-naphthalene化学式
CAS
204449-11-6
化学式
C17H17BrS
mdl
——
分子量
333.292
InChiKey
KFKZCDIOACADDH-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    391.5±42.0 °C(predicted)
  • 密度:
    1.322±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    5.9
  • 重原子数:
    19
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.29
  • 拓扑面积:
    28.2
  • 氢给体数:
    0
  • 氢受体数:
    1

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Aryl or heteroaryl substituted 3,4-dihydroanthracene and aryl or heteroaryl substituted benzo[1,2-g]-chrom-3-ene, benzo[1,2-g]-thiochrom-3-ene and benzo [1,2-g]-1,2-dihydroquinoline derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
    申请人:——
    公开号:US20030130515A1
    公开(公告)日:2003-07-10
    Compounds of the formula 1 where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist and/or retinoid inverse-agonist-like biological activity.
    具有以下式子1的化合物,在规范中定义的符号具有相应的含义,具有类视黄醇、类视黄醇拮抗剂和/或类视黄醇反向激动剂样生物活性。
  • Benzo[1,2-G]-chrom-3-ene, and benzo[1,2-G]-thiochrom-3-ene derivatives
    申请人:Allergan Sales, Inc.
    公开号:US06087505A1
    公开(公告)日:2000-07-11
    Compounds of the formula ##STR1## where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist and/or retinoid inverse-agonist-like biological activity.
    式子为##STR1##的化合物,其中符号的含义在说明书中已定义,具有视黄醇、视黄醇拮抗剂和/或视黄醇逆激动剂类似的生物活性。
  • Aryl substituted 3,4-dihydroanthracene derivatives having retinoid antagonist or retinoid inverse agonist type biological activity
    申请人:Allergan, Inc.
    公开号:US07166726B2
    公开(公告)日:2007-01-23
    Disclosed herein are compounds of the formula wherein R1 is independently H or alkyl of 1 to 6 carbons; R2 is optional and is defined as lower alkyl of 1 to 6 carbons, F, Cl, Br, I, CF3, fluoro substituted alkyl of 1 to 6 carbons, OH, SH, alkoxy of 1 to 6 carbons, or alkylthio of 1 to 6 carbons; n is an integer of between 0 and 2; o is an integer between 0 and 3; R3 is hydrogen, lower alkyl of 1 to 6 carbons, F, Cl, Br or I; R4 is heteroaryl or (R5)p-heteroaryl where the heteroaryl group is 5-membered or 6-membered and has 1 to 3 heteroatoms selected from the group consisting of O, S, and N; p is an integer having the values of 0–5; R5 is F, Cl, Br, I, NO2, N(R8)2, N(R8)CORO8, N(R8)CON(R8)2, OH, OCOR8, OR8, CN, COOH, COOR8, C1-10 alkyl, fluoro substituted C1-10 alkyl, C2-10 alkenyl having 1 to 3 double bonds, C2-10 alkynyl having 1 to 3 triple bonds, or a (trialkyl)silyl or (trialkyl)silyloxy group where the alkyl groups independently have 1 to 6 carbons; A is (CH2)q where q is 0–5, C3-6 branched alkyl, C3-6 cycloalkyl, C2-6 alkenyl having 1 or 2 double bonds, or C2-6 alkynyl having 1 or 2 triple bonds; B is hydrogen, COOH or a pharmaceutically acceptable salt thereof, COORO8, CONR9R10, CH2OH, CH2OR11, CH2OCOR11, CHO, CH(OR12)2, CHOR13O, COR7, CR7(OR12)2, CR7OR13O, or Si(C1-6alkyl)3; R7 is C1-5 alkyl, C3-5 cycloalkyl, or C2-5 alkenyl; R8 is C1-10 alkyl, C1-10 (trimethylsilyl)alkyl, or C5-10 cycloalkyl; R9 and R10 are independently hydrogen, C1-10 alkyl, C5-10 cycloalkyl, phenyl or R12-phenyl; R11 is C1-6 alkyl, phenyl, or R12-phenyl; R12 is C1-6 alkyl; and R13 is divalent alkyl radical of 2–5 carbons.
    本文揭示的是以下化合物:其中R1独立地为H或1至6个碳的烷基;R2是可选的,并定义为1至6个碳的低烷基,F,Cl,Br,I,CF3,1至6个碳的氟代烷基,OH,SH,1至6个碳的烷氧基或烷硫基;n为0至2的整数;o为0至3的整数;R3为氢,1至6个碳的低烷基,F,Cl,Br或I;R4为杂环芳基或(R5)p-杂环芳基,其中杂环芳基为5元或6元,并具有从O,S和N组成的1至3个杂原子;p为0至5的整数;R5为F,Cl,Br,I,NO2,N(R8)2,N(R8)CORO8,N(R8)CON(R8)2,OH,OCOR8,OR8,CN,COOH,COOR8,C1-10烷基,氟代C1-10烷基,具有1至3个双键的C2-10烯基,具有1至3个三键的C2-10炔基,或(三烷基)硅基或(三烷基)硅氧基,其中烷基独立地具有1至6个碳;A为(CH2)q,其中q为0至5,C3-6支链烷基,C3-6环烷基,具有1或2个双键的C2-6烯基,或具有1或2个三键的C2-6炔基;B为氢,COOH或其药学上可接受的盐,COORO8,CONR9R10,CH2OH,CH2OR11,CH2OCOR11,CHO,CH(OR12)2,CHOR13O,COR7,CR7(OR12)2,CR7OR13O或Si(C1-6烷基)3;R7为C1-5烷基,C3-5环烷基或C2-5烯基;R8为C1-10烷基,C1-10(三甲基硅基)烷基或C5-10环烷基;R9和R10独立地为氢,C1-10烷基,C5-10环烷基,苯基或R12-苯基;R11为C1-6烷基,苯基或R12-苯基;R12为C1-6烷基;R13为2-5个碳的双价烷基基团。
  • ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO [1,2-G]CHROM-3-ENE, BENZO[1,2-G]-THIOCHROM-3-ENE AND BENZO [1,2-G]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY
    申请人:Allergan
    公开号:US06538149B1
    公开(公告)日:2003-03-25
    Compounds of the formula where the symbols have the meaning defined in the specification, have retinoid, retinoid antagonist and/or retinoid inverse-agonist-like biological activity.
    符号在规范中定义的公式化合物具有类视黄醇、类视黄醇拮抗剂和/或类视黄醇反向激动剂样的生物活性。
  • ARYL OR HETEROARYL SUBSTITUTED 3,4-DIHYDROANTHRACENE AND ARYL OR HETEROARYL SUBSTITUTED BENZO[1,2-g]-CHROM-3-ENE, BENZO[1,2-g]-THIOCHROM-3-ENE AND BENZO[1,2-g]-1,2-DIHYDROQUINOLINE DERIVATIVES HAVING RETINOID ANTAGONIST OR RETINOID INVERSE AGONIST TYPE BIOLOGICAL ACTIVITY
    申请人:Allergan Sales, Inc.
    公开号:EP0948478B1
    公开(公告)日:2002-04-10
查看更多